International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 05 Issue 05 May 2025

Page No: 679-685

DOI: https://doi.org/10.47191/ijmscrs/v5-i05-02, Impact Factor: 8.188

Emerging Trends in Glaucoma Management: Advancements in Diagnostic Modalities, Therapeutic Interventions, and Personalized Medicine Approaches

Diego Alejandro Ramírez López*[1], Adriana Lorena Martínez Martínez[2], Juan Manuel Garcia huerta[1], Noemí Sarahí Gonzales Escareño[2], Ana Paulina Flores de la Rosa[3], Emily Natalia Flores Vargas[3]

[1]Universidad Autónoma de Guadalajara. Zapopan, Jalisco, Mexico.

[2]Universidad Autónoma de Aguascalientes. Aguascalientes, Mexico.

[3]Universidad Cuauhtémoc, Plantel Aguascalientes. Aguascalientes, Mexico.

ABSTRACT

Glaucoma, a progressive optic neuropathy characterized by retinal ganglion cell degeneration and visual field loss, remains a leading cause of irreversible blindness worldwide. Recent advancements in imaging technologies, minimally invasive surgical techniques (MIGS), and neuroprotective therapies have revolutionized the diagnostic and therapeutic landscape of this multifactorial disease. This article explores contemporary trends in glaucoma care, including the integration of artificial intelligence (AI) in optical coherence tomography (OCT) analysis, the role of biomarkers in early detection, and the paradigm shift toward personalized treatment strategies. Additionally, we review novel pharmacological agents targeting intraocular pressure (IOP)-independent mechanisms, such as Rho kinase inhibitors and adenosine receptor agonists, as well as innovations in sustained-release drug delivery systems. The synthesis of current evidence underscores the importance of a multidisciplinary approach to optimize patient outcomes and mitigate disease progression in at-risk populations.

KEYWORDS: Glaucoma, intraocular pressure (IOP), optical coherence tomography (OCT), minimally invasive glaucoma surgery (MIGS), neuroprotection, artificial intelligence (AI), biomarkers, personalized medicine, Rho kinase inhibitors, sustained-release drug delivery.

ARTICLE DETAILS

Published On:
05 May 2025

Available on:
https://ijmscrs.com/

INTRODUCTION

Glaucoma represents a heterogeneous group of optic neuropathies with complex pathophysiology, involving both mechanical and vascular insults to the optic nerve head. Despite intraocular pressure (IOP) being the primary modifiable risk factor, emerging research highlights the contribution of genetic predisposition, mitochondrial dysfunction, and dysregulated immune responses in disease progression. Traditional management strategies, centered on IOP-lowering therapies, are being supplemented by groundbreaking innovations in diagnostic precision and therapeutic efficacy.1,2

The advent of high-resolution imaging modalities, such as swept-source OCT and adaptive optics, has enhanced the detection of pre-perimetric glaucoma, enabling earlier intervention. Concurrently, the rise of minimally invasive glaucoma surgeries (MIGS)—including trabecular micro-bypass stents and suprachoroidal shunts—offers safer alternatives to traditional trabeculectomy, particularly for patients with mild-to-moderate disease. Furthermore, the application of artificial intelligence (AI) in analyzing structural and functional data holds promise for improving diagnostic accuracy and predicting disease progression.2

Pharmacologically, the development of Rho kinase inhibitors (e.g., netarsudil) and nitric oxide donors (e.g., latanoprostene bunod) exemplifies the shift toward targeting aqueous humor outflow pathways with dual mechanisms of action. Neuroprotective strategies, such as cannabinoid receptor modulation and stem cell therapy, are also under investigation to preserve retinal ganglion cell viability.3

BACKGROUND

Glaucoma, a chronic and insidious optic neuropathy, has long been recognized as one of the most formidable challenges in ophthalmology, standing as the second leading cause of irreversible blindness worldwide. Its pathophysiological complexity arises from the progressive degeneration of retinal ganglion cells (RGCs) and their axons, culminating in characteristic structural changes to the optic nerve head and corresponding visual field defects. Historically, the management of glaucoma has been anchored in the reduction of intraocular pressure (IOP), the sole modifiable risk factor unequivocally linked to disease progression. However, the limitations of this approach have become increasingly apparent, as a significant proportion of patients continue to experience disease progression despite achieving target IOP levels, a phenomenon attributed to IOP-independent mechanisms such as vascular dysregulation, oxidative stress, and neuroinflammatory cascades.4

The evolution of glaucoma diagnostics has been marked by a transition from subjective assessment—reliant on funduscopic examination and perimetric testing—to sophisticated, objective imaging modalities capable of detecting preclinical disease. Optical coherence tomography (OCT), particularly spectral-domain and swept-source variants, has revolutionized the quantification of retinal nerve fiber layer (RNFL) thickness and ganglion cell-inner plexiform layer (GCIPL) metrics, enabling earlier and more precise diagnosis. Additionally, advancements in adaptive optics and confocal scanning laser ophthalmoscopy have provided unprecedented cellular-level insights into optic nerve head morphology. Despite these technological strides, challenges persist in identifying patients at highest risk for rapid progression, spurring investigations into novel biomarkers, including proteomic, genetic, and metabolomic signatures, which may herald a new era of predictive medicine in glaucoma.4

Therapeutically, the past decade has witnessed a paradigm shift from broad, one-size-fits-all treatment strategies toward individualized approaches tailored to a patient's unique risk profile. Pharmacologic management, once dominated by beta-adrenergic antagonists and prostaglandin analogs, has expanded to include novel agents such as Rho kinase inhibitors, which enhance trabecular outflow while exerting potential neuroprotective effects, and nitric oxide-donating compounds, which target both uveoscleral and trabecular pathways. Sustained-release drug delivery systems, including biodegradable implants and punctal plug devices, are emerging as solutions to the pervasive issue of poor adherence to topical therapy, a major contributor to treatment failure.5

Surgical interventions have similarly undergone a transformative evolution, with the advent of minimally invasive glaucoma surgeries (MIGS) redefining the risk-benefit calculus for patients with mild-to-moderate disease. Procedures such as the implantation of trabecular micro-bypass stents (e.g., iStent, Hydrus) and suprachoroidal shunts (e.g., CyPass, now withdrawn but emblematic of the field's trajectory) offer modest IOP reduction with markedly improved safety profiles compared to traditional trabeculectomy or tube shunts. Concurrently, refinements in laser therapies—including selective laser trabeculoplasty (SLT) and micropulse transscleral cyclophotocoagulation—have expanded the repertoire of options for patients across the disease spectrum.5

Perhaps the most tantalizing frontier in glaucoma research lies in the realm of neuroprotection and axonal regeneration. While IOP reduction remains the cornerstone of therapy, the recognition that RGC apoptosis involves multifactorial pathways has spurred investigations into compounds targeting excitotoxicity, mitochondrial dysfunction, and glial cell activation. Experimental approaches, such as stem cell transplantation, gene therapy to enhance neuronal survival, and optogenetic strategies to restore visual signaling, remain in preclinical stages but hold transformative potential.5

Against this backdrop, the integration of artificial intelligence (AI) and machine learning into glaucoma care promises to further refine risk stratification, diagnostic accuracy, and therapeutic decision-making. Algorithms trained on vast datasets of imaging and functional tests are demonstrating remarkable proficiency in detecting early glaucomatous changes and predicting progression rates, potentially enabling a shift from reactive to proactive management.6

Thus, the contemporary landscape of glaucoma is one of both promise and challenge, where cutting-edge science converges with unmet clinical needs. This article seeks to synthesize these dynamic advancements, providing a comprehensive examination of the innovations poised to redefine glaucoma care in the coming decade.6

EMERGING DIAGNOSTIC MODALITIES IN GLAUCOMA: ADVANCING PRECISION AND EARLY DETECTION

Glaucoma, a progressive neurodegenerative disorder of the optic nerve, remains a leading cause of irreversible vision loss worldwide. Its insidious onset and heterogeneous presentation underscore the critical need for advanced diagnostic modalities capable of detecting structural and functional changes at the earliest stages, often before perceptible visual field deficits manifest. Recent years have witnessed remarkable innovations in ophthalmic imaging, functional testing, and biomarker analysis, revolutionizing the diagnostic paradigm for glaucoma. These cutting-edge technologies not only enhance diagnostic accuracy but also refine risk stratification, enabling clinicians to intervene at a stage when therapeutic interventions may exert the greatest neuroprotective effect.6

HIGH-RESOLUTION AND MULTIMODAL IMAGING TECHNOLOGIES

1. Swept-Source Optical Coherence Tomography (SS-OCT)

Traditional spectral-domain OCT (SD-OCT) has long been the gold standard for quantifying retinal nerve fiber layer (RNFL) thickness and ganglion cell complex (GCC) metrics. However, swept-source OCT (SS-OCT) represents a significant leap forward, employing a longer wavelength (1050 nm vs. 840 nm in SD-OCT) to achieve deeper tissue penetration and reduced signal attenuation, particularly in eyes with media opacities. SS-OCT enables high-resolution visualization of the lamina cribrosa, a critical site of axonal injury in glaucoma, and provides enhanced imaging of the choroid, facilitating investigations into vascular contributions to glaucomatous neuropathy. Additionally, its faster acquisition speed minimizes motion artifacts, improving reproducibility in longitudinal monitoring.7

2. Adaptive Optics (AO) Imaging

Adaptive optics, initially developed for astronomical telescopes, has been adapted for ophthalmic use to correct optical aberrations in real time, permitting cellular-level resolution of retinal structures. AO-enhanced scanning laser ophthalmoscopy (AO-SLO) and AO-OCT allow for direct visualization of individual retinal ganglion cells (RGCs), axons, and capillaries in the peripapillary and macular regions. This unprecedented resolution holds promise for detecting the earliest signs of RGC loss before it becomes apparent on conventional imaging. Furthermore, AO facilitates dynamic assessments of blood flow at the capillary level, providing insights into the role of microvascular dysfunction in glaucoma pathogenesis.7

3. Optical Coherence Tomography Angiography (OCTA)

The recognition of vascular dysregulation as a contributor to glaucomatous damage has spurred the adoption of OCT angiography (OCTA), a non-invasive imaging technique that delineates retinal and optic nerve head perfusion without the need for exogenous contrast agents. Unlike traditional fluorescein angiography, OCTA generates three-dimensional maps of the microvasculature, enabling quantification of vessel density in the radial peripapillary capillaries (RPCs) and superficial macular plexus. Studies have demonstrated that reduced peripapillary vessel density precedes detectable RNFL thinning, positioning OCTA as a potential biomarker for pre-perimetric glaucoma. Moreover, its ability to monitor vascular changes over time may help identify "fast progressors" who require more aggressive intervention.7

Advanced Functional and Electrophysiological Assessments

4. Pattern Electroretinography (PERG) and Photopic Negative Response (PhNR)

While standard automated perimetry remains the cornerstone of functional assessment in glaucoma, its subjective nature and reliance on patient cooperation limit its sensitivity in early disease. Pattern electroretinography (PERG) measures RGC electrical activity in response to contrast-reversing stimuli, offering an objective marker of ganglion cell dysfunction. The photopic negative response (PhNR) of the full-field electroretinogram (ERG) similarly reflects RGC integrity and has shown promise in detecting glaucoma before visual field abnormalities emerge. These electrophysiological techniques may be particularly valuable in patients with unreliable perimetry or pre-perimetric disease.8

5. Frequency-Doubling Technology (FDT) and Short-Wavelength Automated Perimetry (SWAP)

Innovations in perimetric testing have sought to selectively evaluate vulnerable subpopulations of RGCs. Frequency-doubling technology (FDT) preferentially assesses magnocellular (M-cell) function, which may be affected early in glaucoma. Short-wavelength automated perimetry (SWAP), or blue-on-yellow perimetry, targets koniocellular pathways, providing complementary data to standard white-on-white perimetry. Recent iterations, such as Matrix FDT and SWAP with improved algorithms, enhance test-retest reliability and diagnostic sensitivity.8

Artificial Intelligence and Machine Learning in Glaucoma Diagnosis

6. Deep Learning Algorithms for Structural and Functional Data Integration

The exponential growth of computational power and big data analytics has propelled artificial intelligence (AI) into the forefront of glaucoma diagnostics. Deep learning models, particularly convolutional neural networks (CNNs), have demonstrated remarkable proficiency in analyzing OCT, fundus photography, and visual field data to detect glaucomatous changes with accuracy rivaling—and in some cases surpassing—that of expert clinicians. These algorithms excel at identifying subtle patterns in imaging biomarkers (e.g., RNFL texture, optic disc topography) that may elude human observation. Furthermore, AI-driven predictive models integrate multimodal data (genetic, demographic, and ocular parameters) to forecast individual progression risk, enabling personalized surveillance strategies.9

7. Telemedicine and Portable Diagnostic Devices

The global burden of glaucoma necessitates scalable screening solutions, particularly in underserved regions. Portable OCT devices, smartphone-based fundus cameras, and handheld tonometers are expanding access to diagnostic testing. When combined with cloud-based AI analysis, these tools facilitate remote screening and teleconsultations, bridging gaps in healthcare disparities.10

Emerging Biomarkers and Molecular Diagnostics

8. Aqueous Humor and Tear Film Proteomics

Liquid biopsy techniques are being explored to identify molecular signatures of glaucoma in aqueous humor and tear film samples. Proteomic analyses have revealed dysregulated proteins involved in oxidative stress, extracellular matrix remodeling, and neurodegeneration, offering potential diagnostic and prognostic biomarkers.11

9. Genetic Risk Profiling and Polygenic Risk Scores (PRS)

Advancements in genome-wide association studies (GWAS) have identified numerous genetic loci associated with glaucoma susceptibility. Polygenic risk scores (PRS) aggregate these genetic variants to stratify individuals by lifetime risk, potentially guiding screening frequency and prophylactic interventions in high-risk cohorts.11

The diagnostic armamentarium for glaucoma is undergoing a transformative expansion, driven by innovations in imaging, functional testing, AI, and molecular biology. These advancements not only enhance early detection but also pave the way for precision medicine approaches tailored to individual risk profiles and disease mechanisms. As these technologies mature, their integration into clinical practice promises to redefine glaucoma management, shifting the paradigm from reactive treatment to proactive preservation of vision.12

PERSONALIZED MEDICINE APPROACHES IN GLAUCOMA: TAILORING DIAGNOSIS AND TREATMENT TO THE INDIVIDUAL PATIENT

Glaucoma, a complex and multifactorial optic neuropathy, has long been managed under a generalized treatment paradigm primarily focused on intraocular pressure (IOP) reduction. However, the growing recognition of its heterogeneous pathophysiology—encompassing genetic predisposition, vascular dysregulation, biomechanical stress, and neuroinflammatory pathways—has underscored the limitations of a one-size-fits-all approach. In response, the field is increasingly embracing personalized medicine, a paradigm that seeks to customize diagnostic and therapeutic strategies based on an individual's unique genetic, molecular, and clinical profile. This shift is being propelled by advancements in genomic medicine, high-resolution imaging, artificial intelligence (AI), and pharmacogenomics, enabling clinicians to move beyond IOP-centric management toward precision therapies that target the underlying mechanisms driving disease progression in specific patient subsets.13

GENETIC PROFILING AND RISK STRATIFICATION

The heritability of primary open-angle glaucoma (POAG) has been well-established through familial aggregation studies and genome-wide association studies (GWAS), which have identified numerous susceptibility loci, including those near *CDKN2B-AS1*, *SIX1/SIX6*, and *CAV1/CAV2*. Polygenic risk scores (PRS), which aggregate the cumulative effect of multiple genetic variants, are emerging as powerful tools for stratifying individuals based on their inherent predisposition to glaucoma. Patients with high PRS may benefit from earlier and more frequent surveillance, including advanced imaging modalities such as optical coherence tomography (OCT) and OCT angiography (OCTA), even in the absence of overt clinical signs. Furthermore, genetic testing can identify rare but high-impact mutations, such as those in *MYOC* (associated with juvenile-onset glaucoma) or *OPTN* (linked to normal-tension glaucoma), which may necessitate more aggressive intervention.14

IMAGING-BASED PHENOTYPING AND PROGRESSION FORECASTING

The structural and functional heterogeneity of glaucoma necessitates individualized monitoring strategies. Advances in machine learning algorithms have enabled the integration of multimodal data—including OCT-derived retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) metrics, and optic nerve head topography—to predict which patients are at highest risk of rapid progression. For instance, eyes with focal lamina cribrosa defects or pronounced peripapillary vessel density loss on OCTA may warrant closer follow-up and lower target IOP thresholds. Similarly, AI-driven predictive models that incorporate longitudinal visual field data can identify "fast progressors" who may benefit from early surgical intervention rather than prolonged medical therapy.15

PHARMACOGENOMICS AND TAILORED MEDICAL THERAPY

The response to IOP-lowering medications varies significantly among individuals, influenced by genetic polymorphisms in drug-metabolizing enzymes (e.g., *CYP2D6*), transporters (e.g., *ABCC1*), and target receptors (e.g., *ADRB1*). Pharmacogenomic profiling holds promise for optimizing topical therapy selection, minimizing adverse effects, and improving adherence. For example, patients with certain *ADRB1* variants may exhibit reduced responsiveness to beta-blockers, making prostaglandin analogs or Rho kinase inhibitors (e.g., netarsudil) more effective first-line options. Additionally, emerging sustained-release drug delivery systems, such as biodegradable implants or punctal plug devices, can be tailored to patients with documented poor adherence, ensuring consistent therapeutic exposure.16

TARGETED SURGICAL AND LASER INTERVENTIONS

The advent of minimally invasive glaucoma surgeries (MIGS) has expanded the repertoire of procedures that can be customized to a patient's anatomical and disease characteristics. For instance, eyes with predominantly trabecular meshwork dysfunction may derive maximal benefit from trabecular bypass stents (e.g., iStent or Hydrus), whereas those with significant suprachoroidal space potential may respond better to cyclodialysis-enhanced devices (e.g., *MINIject*). Similarly, selective laser trabeculoplasty (SLT), which exhibits variable efficacy based on trabecular meshwork pigmentation and inflammatory biomarkers, can be selectively offered to patients with a higher likelihood of response, as predicted by anterior segment imaging or genetic markers.17

NEUROPROTECTION AND DISEASE-MODIFYING THERAPIES

Beyond IOP reduction, personalized neuroprotective strategies are being explored to address the diverse molecular pathways contributing to retinal ganglion cell (RGC) apoptosis. Patients with evidence of mitochondrial dysfunction, as detected by metabolomic profiling of aqueous humor or serum, may benefit from therapies targeting oxidative stress (e.g., coenzyme Q10 analogs or *N*-acetylcysteine). Conversely, those with elevated biomarkers of neuroinflammation (e.g., TNF-α or complement activation) might respond to immunomodulatory agents. Experimental approaches, such as gene therapy to upregulate neurotrophic factors (e.g., *BDNF*) or stem cell-derived RGC transplantation, are being investigated in preclinical models with the goal of individualized regenerative medicine.18

INTEGRATION OF DIGITAL HEALTH AND REMOTE MONITORING

Wearable IOP sensors, smartphone-based perimetry, and home OCT devices are enabling real-time, patient-specific disease tracking. These technologies facilitate dynamic treatment adjustments based on fluctuations in IOP or progression rates, reducing reliance on intermittent clinic visits. AI-powered decision support systems can synthesize this continuous data stream to generate personalized management recommendations, bridging the gap between patient-generated health data and clinical action.18

The era of personalized medicine in glaucoma represents a paradigm shift from empiric treatment to mechanism-based precision care. By leveraging genetic, imaging, and molecular biomarkers, clinicians can now identify high-risk individuals earlier, select optimal therapies based on likely response, and intervene with surgical or neuroprotective strategies tailored to the patient's unique disease endotype. As these approaches mature, they promise to transform glaucoma management from a reactive to a proactive discipline, preserving vision through individualized risk mitigation and biologically targeted interventions. The integration of multi-omics data, advanced analytics, and innovative therapeutics will be pivotal in realizing this vision, ultimately improving outcomes for the diverse spectrum of patients affected by this blinding disease.18

CONCLUSION

Glaucoma, once viewed through the narrow lens of intraocular pressure (IOP) modulation, has emerged as a complex neurodegenerative disorder with multifaceted etiopathogenesis, demanding a comprehensive reevaluation of diagnostic and therapeutic strategies. The convergence of cutting-edge imaging modalities, molecular diagnostics, artificial intelligence, and personalized treatment algorithms has ushered in a new era of precision medicine, fundamentally transforming our approach to this sight-threatening disease. The integration of swept-source optical coherence tomography (SS-OCT), adaptive optics imaging, and optical coherence tomography angiography (OCTA) has redefined early detection, enabling clinicians to identify subclinical structural and microvascular changes long before functional visual field deficits manifest. These technological advancements, coupled with sophisticated electrophysiological assessments such as pattern electroretinography (PERG) and photopic negative response (PhNR), provide an unprecedented window into retinal ganglion cell (RGC) dysfunction, facilitating intervention at stages when neuroprotective strategies may exert maximal efficacy.

The paradigm of personalized medicine has gained substantial traction, driven by insights from genomic medicine and biomarker discovery. Polygenic risk scores (PRS) and targeted genetic testing now allow for stratification of patients based on inherited susceptibility, enabling tailored surveillance protocols and prophylactic measures for high-risk individuals. Pharmacogenomic profiling further refines therapeutic decision-making, optimizing medication selection by predicting individual responses to IOP-lowering agents, thereby minimizing adverse effects and enhancing adherence. The advent of sustained-release drug delivery systems, including biodegradable implants and punctal plug devices, addresses the critical challenge of treatment compliance, ensuring sustained therapeutic exposure in patients with historically poor adherence.

Surgical innovation, particularly the rise of minimally invasive glaucoma surgeries (MIGS), has revolutionized the management of mild-to-moderate disease, offering safer and more predictable outcomes compared to traditional trabeculectomy. The ability to select MIGS devices based on anatomical and pathophysiological characteristics—such as trabecular micro-bypass stents for trabecular meshwork dysfunction or suprachoroidal shunts for enhanced uveoscleral outflow—exemplifies the shift toward individualized surgical planning. Concurrently, advancements in laser therapies, including selective laser trabeculoplasty (SLT) and micropulse transscleral cyclophotocoagulation (MP-TSCPC), provide additional options for customized intervention, particularly in patients who may not tolerate or adhere to pharmacologic regimens.

Perhaps the most promising frontier lies in the development of neuroprotective and regenerative therapies, which target the underlying mechanisms of RGC apoptosis rather than merely lowering IOP. From Rho kinase inhibitors with dual IOP-lowering and neuroprotective properties to experimental interventions such as stem cell transplantation and gene therapy, these approaches herald a future where disease modification—not just symptomatic management—becomes a clinical reality. The identification of specific molecular signatures in aqueous humor and tear film, alongside metabolomic and proteomic profiling, may soon enable clinicians to match patients with targeted neuroprotective agents based on their unique disease endotype.

Artificial intelligence and machine learning have further cemented their role as indispensable tools in glaucoma care, integrating multimodal data to predict disease progression, optimize treatment plans, and even guide surgical decision-making. The rise of telemedicine and portable diagnostic devices extends the reach of these innovations, ensuring equitable access to advanced glaucoma care across diverse populations.

In summary, the management of glaucoma is undergoing a transformative evolution, propelled by technological innovation, biological insights, and a deepening understanding of disease heterogeneity. The transition from a reactive, IOP-centric model to a proactive, precision-based approach holds immense promise for preserving vision and improving quality of life for millions of patients worldwide. As these advancements continue to mature, the future of glaucoma care lies in the seamless integration of early detection, personalized therapeutics, and neuroprotective strategies—a holistic vision that transcends traditional boundaries and redefines what is possible in the fight against this blinding disease.

REFERENCES

I. Tham, Y.C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. *Ophthalmology* 2014, *121*, 2081–2090.

II. Heijl, A.; Leske, M.C.; Bengtsson, B.; Hyman, L.; Bengtsson, B.; Hussein, M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. *Arch. Ophthalmol.* 2002, *120*, 1268–1279.

III. Coan, L.J.; Williams, B.M.; Krishna Adithya, V.; Upadhyaya, S.; Alkafri, A.; Czanner, S.; Venkatesh, R.; Willoughby, C.E.; Kavitha, S.; Czanner, G. Automatic detection of glaucoma via fundus imaging and artificial intelligence: A review. *Surv. Ophthalmol.* 2023, *68*, 17–41.

IV. Zhu, Y.; Salowe, R.; Chow, C.; Li, S.; Bastani, O.; O'Brien, J.M. Advancing Glaucoma Care: Integrating Artificial Intelligence in Diagnosis, Management, and Progression Detection. *Bioengineering* 2024, *11*, 122. [

V. Barry, S.; Wang, S.Y. Predicting Glaucoma Surgical Outcomes Using Neural Networks and Machine Learning on Electronic Health Records. *Transl. Vis. Sci. Technol.* 2024, *13*, 15.

VI. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. *Am. J. Ophthalmol.* 2000, *130*, 429–440.

VII. Kim, J.; Park, J.; Park, Y.G.; Cha, E.; Ku, M.; An, H.S.; Lee, K.P.; Huh, M.I.; Kim, J.; Kim, T.S.; et al. A soft and transparent contact lens for the wireless quantitative monitoring of intraocular pressure. *Nat. Biomed. Eng.*2021, *5*, 772–782.

VIII. Zhang, Y.; Wei, Y.; Lee, C.H.C.; Or, P.W.; Karunaratne, I.K.; Deng, M.; Yang, W.; Chong, I.T.; Yang, Y.; Chen, Z.; et al. Continuous 24-hour intraocular pressure monitoring in normal Chinese adults using a novel contact lens sensor system. *Br. J. Ophthalmol.* 2024, *108*, 1535–1542.

IX. Gillmann, K.; Wasilewicz, R.; Hoskens, K.; Simon-Zoula, S.; Mansouri, K. Continuous 24-hour measurement of intraocular pressure in millimeters of mercury (mmHg) using a novel contact lens sensor: Comparison with pneumatonometry. *PLoS ONE* 2021, *16*, e0248211.

X. Wasilewicz, R.; Varidel, T.; Simon-Zoula, S.; Schlund, M.; Cerboni, S.; Mansouri, K. First-in-human continuous 24-hour measurement of intraocular pressure and ocular pulsation using a novel contact lens sensor. *Br. J. Ophthalmol.* 2020, *104*, 1519–1523.

XI. Yang, Z.; Tatham, A.J.; Zangwill, L.M.; Weinreb, R.N.; Zhang, C.; Medeiros, F.A. Diagnostic ability of retinal nerve fiber layer imaging by swept-source optical coherence tomography in glaucoma. *Am. J. Ophthalmol.*2015, *159*, 193–201.

XII. Kim, Y.W.; Lee, J.; Kim, J.S.; Park, K.H. Diagnostic Accuracy of Wide-Field Map from Swept-Source Optical Coherence Tomography for Primary Open-Angle Glaucoma in Myopic Eyes. *Am. J. Ophthalmol.* 2020, *218*, 182–191.

XIII. Janssens, R.; van Rijn, L.J.; Eggink, C.A.; Jansonius, N.M.; Janssen, S.F. Ultrasound biomicroscopy of the anterior segment in patients with primary congenital glaucoma: A review of the literature. *Acta Ophthalmol.*2022, *100*, 605–613.

XIV. Xu, Q.; Zhang, Y.; Wang, L.; Chen, X.; Sun, X.; Chen, Y. The correlation of anterior segment structures in primary congenital glaucoma by ultrasound biomicroscopy with disease severity and surgical outcomes. *Graefes Arch. Clin. Exp. Ophthalmol.* 2024, *262*, 1245–1252.

XV. Chen, L.; Xiong, K.; Wu, J. Comparison of anterior chamber depth measured by anterior segment optical coherence tomography and ultrasound biomicroscopy: A meta-analysis. *Nan Fang Yi Ke Da Xue Xue Bao*2013, *33*, 1533–1537.

XVI. Alexander, J.L.; Wei, L.; Palmer, J.; Darras, A.; Levin, M.R.; Berry, J.L.; Ludeman, E. A systematic review of ultrasound biomicroscopy use in pediatric ophthalmology. *Eye* 2021, *35*, 265–276. Wang, S.B.; Cornish, E.E.; Grigg, J.R.; McCluskey, P.J. Anterior segment optical coherence tomography and its clinical applications. *Clin. Exp. Optom.* 2019, *102*, 195–207.

XVII. Desmond, T.; Tran, V.; Maharaj, M.; Carnt, N.; White, A. Diagnostic accuracy of AS-OCT vs gonioscopy for detecting angle closure: A systematic review and meta-analysis. *Graefes Arch. Clin. Exp. Ophthalmol.* 2022, *260*, 1–23

XVIII. Olyntho, M.A.C., Jr.; Jorge, C.A.C.; Castanha, E.B.; Gonçalves, A.N.; Silva, B.L.; Nogueira, B.V.; Lima, G.M.; Gracitelli, C.P.B.; Tatham, A.J. Artificial Intelligence in Anterior Chamber Evaluation: A Systematic Review and Meta-Analysis. *J. Glaucoma* 2024, *33*, 658–664.